0001061983-21-000247.txt : 20211102
0001061983-21-000247.hdr.sgml : 20211102
20211102171643
ACCESSION NUMBER: 0001061983-21-000247
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211101
FILED AS OF DATE: 20211102
DATE AS OF CHANGE: 20211102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cragg David
CENTRAL INDEX KEY: 0001316459
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50633
FILM NUMBER: 211372522
MAIL ADDRESS:
STREET 1: 280 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CYTOKINETICS INC
CENTRAL INDEX KEY: 0001061983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943291317
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 280 EAST GRAND AVENUE
STREET 2: .
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 624-3000
MAIL ADDRESS:
STREET 1: 280 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2021-11-01
0
0001061983
CYTOKINETICS INC
CYTK
0001316459
Cragg David
280 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief HR & Admin Officer
Common Stock
2021-11-01
4
M
0
6675
6.0
A
145379
D
Common Stock
2021-11-01
4
S
0
6675
34.8896
D
138704
D
Common Stock
2021-11-01
4
M
0
18325
6.0
A
157029
D
Common Stock
2021-11-01
4
S
0
18325
34.8896
D
138704
D
Incentive Stock Option (right to buy)
6.0
2021-11-01
4
M
0
18325
0.0
D
2013-04-05
2023-03-05
Common Stock
18325
0
D
Non-Qualified Stock Option (right to buy)
6.0
2021-11-01
4
M
0
6675
0.0
D
2013-04-05
2023-03-05
Common Stock
6675
0
D
Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total.
Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.
Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.
By: Robert Wong For: David Cragg
2021-11-02